Pfizer names Cecile Guegan as permanent CFO
Her annual incentive target equals her $1,300,000 base salary and is determined based on salary paid during the year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Pfizer Inc. (PFE) appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026, after she served as interim CFO beginning August 16, 2026. The board unanimously elected her to the permanent role.
Her annual base salary is $1,300,000, with an annual target cash incentive opportunity of $1,300,000, equal to 100% of base salary and determined based on salary paid during the year. Guegan has more than 25 years of pharmaceutical finance experience and served as senior vice president of finance for Pfizer’s Global Biopharmaceuticals business beginning in 2022.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Annual base salary: $1,300,000
Annual target cash incentive opportunity: $1,300,000
Target incentive as a share of base salary: 100%
+3 more
6 metrics
Annual base salary
$1,300,000
For the CFO role
Annual target cash incentive opportunity
$1,300,000
Equal to 100% of annual base salary
Target incentive as a share of base salary
100%
Annual target cash incentive opportunity
CFO appointment effective date
November 1, 2026
Cecile Guegan
Interim CFO start date
August 16, 2026
Cecile Guegan
Pharmaceutical finance experience
More than 25 years
Cecile Guegan
Key Terms
annual target cash incentive opportunity, capital allocation, operations planning and analysis (OP&A), corporate controllership
4 terms
annual target cash incentive opportunity financial
"an annual target cash incentive opportunity of $1,300,000"
capital allocation financial
"a disciplined approach to capital allocation"
Capital allocation is the process of deciding how a company or individual uses their money to grow, pay bills, save, or invest. It matters because good decisions can help build wealth and ensure resources are used wisely, while poor choices can limit growth or cause financial problems. Think of it like managing your allowance—deciding whether to spend, save, or invest to meet your goals.
operations planning and analysis (OP&A) financial
"operations planning and analysis (OP&A)"
corporate controllership financial
"corporate controllership"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is PFE's CFO, and when did she take the role?
Cecile Guegan became Pfizer's chief financial officer and executive vice president effective November 1, 2026, after serving as interim CFO since August 16, 2026. The board unanimously elected her to the permanent role.
What is Cecile Guegan's compensation as PFE's CFO?
Guegan's annual base salary is $1,300,000, and her annual target cash incentive opportunity is also $1,300,000. The target equals 100% of her annual base salary and is determined based on salary paid during the year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2026
(Exact name of registrant as specified in its charter)
| (State or other | (Commission File | (I.R.S. Employer | ||||||
| jurisdiction of | Number) | Identification No.) | ||||||
| incorporation) | ||||||||
| (Zip Code) | ||||||||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | |||||||||||||
On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses. At Pfizer, she has held successive finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group. Immediately before her appointment as Interim Chief Financial Officer, she served as Senior Vice President of Finance for Pfizer’s Global Biopharmaceuticals business since 2022 and Vice President, Finance, Research & Development and Business Office from 2020 to 2022. Ms. Guegan holds a master’s degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor’s degree in Accounting (French DECF). In connection with Ms. Guegan’s election, the Compensation Committee of the Board of Directors of the Company unanimously approved the following compensation arrangements for Ms. Guegan as of the Effective Date: (1) an annual base salary of $1,300,000; and (2) an annual target cash incentive opportunity of $1,300,000, which represents 100% of her annual base salary, which will be determined based on the salary paid during the year. A copy of the Company’s press release announcing Ms. Guegan’s appointment is attached as Exhibit 99.1 and is incorporated herein by reference. | ||||||||||||||
Item 9.01 Financial Statements and Exhibits
| (d) Exhibits | ||||||||
| Exhibit Number | Exhibit Description | |||||||
99.1 | Press Release of Pfizer Inc. dated November 3, 2026 | |||||||
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PFIZER INC. | ||||||||
| Dated: November 3, 2026 | By: | /s/ Margaret M. Madden | ||||||
| Margaret M. Madden | ||||||||
| Senior Vice President and Corporate Secretary | ||||||||
| Chief Governance Counsel | ||||||||
Exhibit 99.1
 | |||||
Pfizer Appoints Cecile Guegan as Chief Financial Officer
Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience
NEW YORK, November 3, 2026—Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company’s financial operations, execution and strategic planning.
“Cecile is an exceptional finance leader who knows our company and industry deeply, and she has a proven track record of optimizing financial performance while fueling growth,” said Albert Bourla, Chairman and Chief Executive Officer. “Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands as we aim for meaningful growth. I’m confident she will help us execute with discipline and ambition as we work to deliver for our patients and shareholders.”
“I am honored to step into this role to continue positioning Pfizer for durable long-term growth and shareholder value creation,” said Cecile Guegan, Chief Financial Officer and Executive Vice President, Pfizer. “My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond.”
Cecile will oversee every aspect of the Company’s financial management. She will be responsible for all corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis (OP&A), corporate controllership, and business finance and analytics.
Prior to stepping into the interim finance leadership role, Cecile was directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. In previous positions, Cecile served as a strategic partner to group presidents and chief commercial officers, led long-term forecasting for key product portfolios, led
major enterprise acquisitions and integrations and co-led a strategic initiative to identify new sources of growth.
She holds a master’s degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF).
For a complete list of Pfizer’s executive leadership team, please visit Leadership | Pfizer.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this release is as of November 3, 2026. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about, among other things, Pfizer’s growth potential, strategy, prospects and actions designed to create shareholder value that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; risks related to the ability to realize the anticipated benefits of Pfizer’s business development transactions, including the possibility that the expected benefits from such transactions will not be realized or will not be realized within the expected time period; uncertainties regarding the commercial potential of Pfizer's products and product candidates; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in
2
Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, trade policies or economies generally; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; the impact of COVID-19 on our business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
# # #
Media Contact:
PfizerMediaRelations@Pfizer.com
Investor Contact:
IR@Pfizer.com
3